



OvaScience Announces Creation of International Product Advisory Board

July 8, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 8, 2013-- [OvaScienceSM](#), (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the creation of an International Product Advisory Board (IPAB). Comprised of fertility experts, the IPAB will assist OvaScience in the development and commercialization of its technologies worldwide. OvaScience convened the inaugural meeting of the IPAB during the European Society of Human Reproduction and Embryology (ESHRE) 2013 Annual Meeting, [the world's leading event in reproductive science and medicine](#), being held this week in London.

"Establishing an International Product Advisory Board and hosting our first meeting during ESHRE are important steps toward our goal of bringing new treatment options to women with infertility throughout the world," said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. "One in six couples worldwide experience some form of infertility problem,¹ and the global fertility market is nearly 10 times larger than the U.S. alone. We look forward to collaborating with our international advisors to transform OvaScience's innovative technologies into new treatments for female infertility."

Members of OvaScience's International Product Advisory Board include:

- **Ernesto Bosch, M.D.**, Director, Human Reproduction Unit, Instituto Valenciano de Infertilidad in Valencia, Spain. Dr. Bosch is a former obstetrics and gynecology specialist at the Hospital La Fe in Valencia and an author of peer-reviewed journal articles on the myriad topics surrounding infertility and assisted reproductive technologies.
- **Klaus Buhler, M.D.**, Chairman, German National IVF Registry and President, German Center for Gynaecology, Endocrinology and Reproductive Medicine. Additionally, Dr. Buhler is a member of ESHRE's European IVF Monitoring Group and a member of the Editorial Board of the Journal of Reproductive Medicine and Endocrinology.
- **Gabor Kovacs, M.D.**, Professor of Obstetrics and Gynecology, Monash University and International Medical Director, Monash IVF. Dr. Kovacs is a former President of the Fertility Society of Australia and former Chairman of the IVF Directors' Group of Australia.
- **Markus Montag, Ph.D.**, Ilabcomm GmbH, St. Augustin, Germany, International reprob lab consulting. Dr. Montag is Co-Founder of the fertility preservation network FertiProtekt and was previously the Director of the Reproductive Biology Laboratory at the University Clinics of Bonn.
- **Geoffrey Trew, M.D.**, Honorary Senior Lecturer, Imperial College London and Consultant in Reproductive Medicine and Surgery, Imperial College Healthcare NHS Trust. Dr. Trew is the former Chief of Service of Reproductive Medicine at the Imperial College NHS Trust and is an author of both book chapters and peer-reviewed journal articles on numerous topics surrounding infertility and assisted reproductive technologies.

About OvaScience

OvaScience (NASDAQ: OVAS) is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility. The Company's patented technology is based on the discovery of egg precursor cells (EggPCSM), which are found in the ovaries. By applying proprietary technology to identify and purify EggPCs, OvaScience is developing potential next generation *in vitro* fertilization (IVF) technologies. The Company currently has two product candidates in development: OvaTureSM, which seeks to create mature fertilizable eggs from a woman's own EggPCs without the need for hormone injections, and AUGMENTSM, which aims to improve egg quality and increase the success of IVF. OvaScience's team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine. For more information, please visit www.ovascience.com and connect with us on [Twitter](#) and [Facebook](#).

Forward-Looking Statements

This press release includes forward-looking statements about the prospects for the Company's technology in addressing female infertility, the Company's strategy, future plans and prospects, including statements regarding the development and planned launch of the Company's product candidates, including AUGMENT. Any statements in this release about our strategy, plans, prospects and future expectations, financial position and

operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “aim,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our expectations regarding the regulatory approvals required for AUGMENT; the science underlying our two product candidates (AUGMENT and OvaTure), which is unproven; our ability to obtain, maintain and protect intellectual property utilized by our products; our ability to obtain additional funding to support our activities; our dependence on third parties; the successful development of, and ability to obtain regulatory approval for, our product candidates; our ability to commercialize our product candidates, including AUGMENT, on the timeline we expect, if at all; competition from others; and our short operating history; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.

¹European Society of Human Reproduction and Embryology (ESHRE), 2011

Source: OvaScience

OvaScience, Inc.
Theresa McNeely, 617-299-7356
EVP, Corporate Communications
tmcneely@ovascience.com